Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Glucagon Clearance is Preserved in Type 2 Diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Measurement of plasma glucagon in humans: A shift in the performance of a current commercially available radioimmunoassay kit

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Influence of NAFLD and bariatric surgery on hepatic and adipose tissue mitochondrial biogenesis and respiration

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Circulating Concentrations of C-Type Natriuretic Peptides Increase with Sacubitril/Valsartan Treatment in Healthy Young Men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. A knowledge graph to interpret clinical proteomics data

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Dynamic human liver proteome atlas reveals functional insights into disease pathways

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Hyperglucagonemia is a common observation in both obesity and type 2 diabetes, and the etiology is primarily thought to be hypersecretion of glucagon. We investigated whether altered elimination kinetics of glucagon could contribute to the hyperglucagonemia in type 2 diabetes and obesity. Individuals with type 2 diabetes and preserved kidney function (8 with and 8 without obesity) and matched control individuals (8 with and 8 without obesity) were recruited. Each participant underwent a 1-hour glucagon infusion (4 ng/kg/min), achieving steady-state plasma glucagon concentrations, followed by a 1-hour wash-out period. Plasma levels, the metabolic clearance rate (MCR), half-life (T½) and volume of distribution of glucagon were evaluated and a pharmacokinetic model was constructed. Glucagon MCR and volume of distribution were significantly higher in the type 2 diabetes group compared to the control group, while no significant differences between the groups were found in glucagon T½ Individuals with obesity had neither a significantly decreased MCR, T½, nor volume of distribution of glucagon. In our pharmacokinetic model, glucagon MCR associated positively with fasting plasma glucose and negatively with body weight. In conclusion, our results suggest that impaired glucagon clearance is not a fundamental part of the hyperglucagonemia observed in obesity and type 2 diabetes.

OriginalsprogEngelsk
TidsskriftDiabetes
Vol/bind71
Udgave nummer1
Sider (fra-til)73-82
Antal sider10
ISSN0012-1797
DOI
StatusUdgivet - jan. 2022

Bibliografisk note

© 2021 by the American Diabetes Association.

ID: 68600421